KR20120094177A - A composition comprising mixed herbal extract of cnidii rhizoma and corydalis tuber for treating or preventing respiratory disease - Google Patents

Abstract

PURPOSE: A composition for prevention or treatment of respiratory diseases which contains mixed herb extracts of corydalis tuber and cnidii rhizoma is provided to promote 5- lipoxygenase inhibiting activities, airway narrowing inhibiting activities, airway inflammation inhibitory actions and ear edema antiphlogistic actions. CONSTITUTION: A composition for prevention or treatment of respiratory diseases contains mixed herb extracts of corydalis tuber and cnidii rhizoma using the lower grade alcohol having 1-4 carbons or 10-95% alcohol aqueous solution thereof. The extract is an extract refined by ethyl acetate, dichloromethane or butanol. The herb medicine mixing weight rate of Cnidii Rhizoma to Corydalis Tuber is 0.1:1-10:1. The herb medicine mixing weight rate of the Cnidii Rhizoma to Corydalis Tuber is 0.5:1-5:1. The respiratory disease is asthma, chronic obstructive lung disease, allergic rhinitis, bronchial adenoma, tuberculosis, pyothorax, lung abscess, terror discharge of phlegm, bronchitis, sore throat, tonsillitis or laryngitis. The health supplement for prevention or improvement of the respiratory disease includes mixed herb extracts of corydalis tuber and cnidii rhizoma using the lower grade alcohol having 1-4 carbons or 10-95% alcohol aqueous solution thereof.

Description

A composition comprising mixed herbal extract of Cnidii Rhizoma and Corydalis Tuber for treating or preventing respiratory disease}

The present invention relates to a composition for the prophylaxis or treatment of respiratory diseases containing a mixed extract of Cnidii Rhizoma and Corydalis Tuber as an active ingredient, and more specifically, the extract of the mixed extract of Cnidii Rhizoma and Corydalis is 5-leaf. Asthma, chronic obstructive pulmonary disease, acute bronchitis, allergic rhinitis, antitussive expectoration, acute respiratory tract infection (bronchitis and bronchiolitis), Provided are compositions useful for the prevention or treatment of respiratory diseases such as acute upper respiratory tract infections such as sore throat, tonsillitis, and laryngitis.

Asthma, chronic obstructive pulmonary disease, allergic rhinitis, Jinhae expectoration, acute bronchitis, bronchiolitis, pharyngitis, tonsillitis, laryngitis are typical diseases of respiratory diseases.

Asthma refers to chronic inflammation of the airways, especially the bronchus. Inflammation caused by asthma can be exacerbated by a wide variety of predispositions, including soot, allergens, cold winds, exercise, and respiratory infections. Persistent inflammation causes airway deformity and hyper-responsiveness. These causes include general symptoms such as wheezing (a narrowing of the airways, wheezing or crotch breathing), a shortness of breath, coughing, and excessive sputum.

Asthma can be summarized as four pathological symptoms: markedly increased influx of eosinophils in the airways, excessive secretion of mucus, edema observed, and above all, airway It becomes characteristic characteristic that) narrows.

The respiratory tract consists of muscles called mucosa and bronchial smooth muscle, and there are many secretory glands in the mucosa, which continue to secrete the necessary secretions. When the bronchial smooth muscle contracts, the respiratory tract becomes narrow. Inflammation, caused by a variety of predispositions such as fumes, allergens, cold air, exercise, and respiratory infections, increases the secretions from the secretory glands, which block the airways, causing the mucous membrane to swell into the airways, narrowing the airways. . Because of this, seizure cough and dyspnea with severe wheezing appear severely, and during the seizure, a dry cough occurs and you feel chest compressions. Many people with asthma have difficulty breathing without knowing the cause of chronic cough and chest compressions. These symptoms tend to appear suddenly in everyday life.

Currently, the concept of asthma has been newly established from bronchial stenosis to chronic bronchial inflammatory disease, and it is important to alleviate symptoms when there is a symptom, but it is important to manage the inflammation in the long term.

Asthma is a pathological / physiological cause of airway inflammation, airway-hyperresponsiveness (AHR), mucin hypersecretion, and immunologically invasive eosinophils. It is a chronic airway inflammatory disease, characterized by an increase in the number of Th2 cells and an increase in the number of activated mast cells. Asthma symptoms are characterized by the infiltration of eosinophils, granulocyte lineages, into the airways, and eosinophils play a very important role in the pathology / physiology of asthma by producing various triggers that promote airway inflammation and bronchial contraction. To perform. Asthma-causing antigens cause differentiation of T cells into Th2 cells, and Th2 cells, such as IL (interleukin) -5, granulocyte-macrophage stimulating factor (GM-CSF), IL-3, IL-13, and IL-4 Cytokines are secreted, and IL-4 acts on B cells to promote the production of IgE and to activate mast cells. When inflammatory cells, such as mast cells, are activated, various inflammatory mediators are advantageous and cause acute inflammatory reactions such as bronchial contraction, vasodilation, sensory nerve sensitization, and cholinergic bronchoconstriction. Most asthma is reversible, but in some patients, asthma progresses, remodeling occurs due to fibrosis of the upper and lower cells, an increase in the number of blood vessels and mucous secretions, and changes in the airway structure due to thickening of airway smooth muscle, and chronic obstructive pulmonary disease. Airway obstruction may also occur in Chronic Obstructive Pulmonary Disease (COPD).

Chronic obstructive pulmonary disease refers to a group of diseases in which airflow obstruction occurs and the air velocity decreases without causing lung disease or heart disease. Clinically, when chronic bronchitis with cough with chronic sputum and alveolar alveoli below the end-bronchial bronchi are abnormally expanded and the emphysema with which the alveolar septum is destroyed is difficult to distinguish, these are collectively referred to as chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease, similar to asthma, symptoms of respiratory distress, cough, sputum and other airway disease symptoms worsen lung function eventually leading to death. The main cause of the disease is smoking, in addition to pollution and congenital diseases, respiratory infections, and the cause is caused by neutrophils (macrophage) and macrophages (macrophage) is known. Neutrophils are representative inflammatory cells that secrete several types of proteases, causing the destruction of lung parenchyma and chronic mucus secretion. Macrophages are important inflammatory cells of IFN-γ (interferon-γ) and IL-13 overexpression. In addition to secreting mediators that cause tissue damage (reactive oxygen species [ROS], NO [nitric oxide] metabolites, etc.), they are also involved in wound healing (TGF-β [transforming growth factor-β], FGF2 [fibroblast growth factor 2], VEGF [endothelial growth factor], etc.) is a cell that causes the chronic inflammation to secrete. Irreversible airway obstruction is characterized by small airway fibrosis (obstructive bronchiolitis), which is characterized by fibrosis due to pulmonary emphysema caused by destruction of the alveoli and inflammation of the small airways and subsequent repetitive damage. There is this. Most patients with these diseases are accompanied by emphysema and inflammation of the small airways and fibrosis.

Both asthma and chronic obstructive pulmonary disease show symptoms of respiratory distress, cough, and sputum, and there are no common causes of the cure for the disease itself. Currently, there are only two treatments for asthma, which are inflammation inhibitors and relief agents that alleviate respiratory distress. This is because the appearance of asthma is similar to that caused by a wide variety of pathogens and triggers. In addition, it is thought that it is difficult to study the disease itself. In particular, the majority of severe asthma, which accounts for a large portion of asthma-related total mortality and economic burden, is treated with high-dose steroids, but there is still a problem that asthma is not well controlled. Asthma treatment should be combined with drug therapy, environmental therapy (hemotherapy), and immunotherapy, and if left for asthma for a long time, a scar on the mucous membrane of the bronchus will be unrecoverable, and as a result, asthma is often worsened. It is important to treat it thoroughly, and inflammatory treatment of the bronchial mucosa continues, even if symptoms disappear, resulting in bronchial damage. Asthma can be chronically and temporarily improved and then recur, and even worse, even during treatment, especially when pediatric asthma is actively treated early, reducing the number of asthma attacks and reducing the degree of seizures. Asthma is an allergic disease, so it is not easy to treat, and unless it is fundamentally treated, it will easily recur when exposed to the triggering environment, so thorough environmental management such as drug therapy is required.

Another typical respiratory disease, allergic rhinitis, also known as nasal allergy or allergic rhinitis, symptoms suddenly sneezing in succession, clear runny nose, large amounts of nasal congestion, and at the same time the head is heavy and tears. The symptoms are very similar, but the antigen is not clear is called vasomotor rhinitis. In other words, when you wake up in the morning of the day and the body temporarily cools, the symptoms as described above may occur and heal in a few hours. It is often confused with a cold, which is different from the common cold, often accompanied by asthma or hives.

Allergic reactions of allergic rhinitis include a kind of antigen and antibody hypersensitivity, release of histamine from the membranes of mast cells and basophils, release of arachidonic acid, and cyclooxygenase (COX) and 5-lipoxygenase. Prostaglandins and leukotrienes are produced by (5-lipoxygenase, 5-LO) to mediate the initial response between 2 to 90 minutes of antigen exposure and the late response after 4 to 8 hours. The initial response is mainly due to the mediator and the late response is mainly due to the cell infiltration. In addition, allergic and nonallergic rhinitis both act as risk factors for the development of asthma. Treatment of allergic rhinitis involves desensitization when the antigen is clear, and there are other drug therapies, surgical therapies, and physical therapies, but it is difficult to cure them completely.

Jinhae expectoration refers to cough sputum caused by physicochemical factors such as cold air, external foreign substances including pathogenic microorganisms, air pollutants, and allergens. Coughing is a reflexive defense mechanism caused by airway mucosal stimulation that, when prolonged coughing caused by excessive stimulation, reduces and worsens the quality of life of the patient. In addition, when dust or irritants are introduced from the outside in the same principle as coughing, the body's bronchus pushes the muscles out with saliva along with saliva, which is the cause of sputum (sputum) formation and inflammation caused by bronchial inflammation such as the lungs. There is a thick purulent sputum.

Acute bronchitis is not a separate disease but is accompanied by other upper and lower extremities. Acute bronchitis often comes with upper respiratory infections such as nasopharyngitis and influenza, whooping cough, measles, typhoid fever, diphtheria, scarlet fever infections, and all but bacterial diseases are due to viral infections. Occasionally, sputum is found in pneumococci, Staphylococcus aureus, Haemophilus influenzae, and various types of research, but this does not mean that bacterial infections are the cause, and antibiotic treatment does not affect the course of the disease. The main symptoms are redness, swelling, and dryness in the bronchial mucosa, mucus or purulent secretions can be seen in the bronchus. It usually recovers without causing complications, but when it is chronically developed, it causes swelling, thickening, and atrophy of the mucous membrane, which can lead to proliferation of fibers, bronchial stenosis, and emphysema. .

Chronic bronchitis is a sputum that lasts for more than three months a year for two consecutive years and coughs persist. Stimulation of smoking, air pollution, occupational exposure, etc. causes bronchial damage, which is thought to cause chronic bronchitis. Chronic coughing, sputum, and difficulty breathing are the main symptoms. As the disease progresses, respiratory distress gradually develops over several months and years, resulting in difficulty in breathing even with a slight activity.

Laryngitis is caused by inflammation of the larynx itself by infection with viruses or bacteria, or by inflammation of surrounding tissues such as pharyngitis and tonsillitis spread to the larynx. This is often a partial symptom of a cold, most often accompanied by a cold (acute rhinitis) or pharyngitis, coughing, and voice changes. Laryngitis is an infectious disease commonly referred to as upper respiratory tract disease, and it is difficult to clearly distinguish it from pharyngitis, laryngitis and bronchitis.

Bronchiolitis (bronchiolitis) is an inflammation of the lungs causing dyspnea, also known as bronchitis. Inflammation of the lining of the bronchioles causes the inner wall cells to clump or swell, resulting in narrowing of the lumen and thus shortness of breath, contagious and often prevalent. The bronchioles carry air from the bronchus to the alveoli and the alveoli supply oxygen to the blood. The cause may be a virus or bacteria infection or both. In some cases, the disease develops with each cold. Risk factors include, among others, diseases that reduce resistance, particularly respiratory infections, family history of allergic diseases, and obesity. Complications include permanent pulmonary disease, chronic bronchitis, partial collapse of the lungs, bronchiectasis, recurrence of pneumonia, and rarely chronic obstructive pulmonary disease.

Sore throat (laryngopharyngitis) is a common cold, throat and upper respiratory tract infection. Beta hemolytic streptococci, staphylococci, pneumonia, bacteria such as Haemophilus and anaerobic strains or viruses such as influenza virus, herpes simplex virus, parainfluenza virus, coxsackie virus, echo virus, etc. Inflammation of the upper respiratory tract mucosa, including acute and chronic. Acute is caused by rapid temperature changes, colds, febrile illnesses, overwork, weak constitution, bacterial infections, and chronic recurrences of acute sore throat, excessive smoking, drinking, overwork, irritating food intake, neck overuse, This may be caused by a sore throat reflux disease. Rarely, it may be caused by inhaling irritating gases, chemicals, or chemical vapors, or by spreading inflammation from adjacent areas such as the sinuses.

As described above, respiratory diseases such as asthma, chronic obstructive pulmonary disease, allergic rhinitis, antitussive expectoration, acute bronchitis, bronchiolitis, sore throat, tonsillitis and laryngitis have some differences in their causes and symptoms, but they are inflammatory diseases. Among the drugs currently in use, airway dilators do not have an effect on inflammation that aggravates the disease and simply relieve symptoms. In addition, steroids, which are known to be effective against inflammation, are problematic for long-term use due to serious side effects. Therefore, a combination of the two is often prescribed, but due to the side effects of steroids developed in the form of inhalants than the oral drug is difficult to take, there is a problem in taking compliance.

Therefore, there is an urgent need to develop new therapeutic agents that can overcome the limitations of these current drug therapies, thereby fundamentally treating the cause and effectively improving the symptoms. However, respiratory diseases are involved in various leukocyte cells and various cytokines and inflammatory mediators that are released here. Therefore, it is thought that effective treatment with single-component synthetic drugs is difficult. It seems to be an effective treatment.

To this end, the present invention provides a mixed extract of the uterus and corydalis as a composition for preventing or treating the respiratory diseases described above.

Cnidii Rhizoma is a perennial herb belonging to the Umbelliferae, a medicinal resource plant using the root stem of Ligusticum chuanxiong Hort. Or Cnidium officinale Makino. Main components include essential oils such as nidlide, z-ligustilide, butylidenephthalide and senkyunolide (Chem. Pharm. Bull., 1984, 32) Phenolic substances (Yakugaku zasshi, 1989, 109, 402-406), 3770-3773; Korean J. Phamacogn., 1990, 21, 69-73), ferulic acid, chlorogenic acid, etc. ) Is known. Cheongung is known for its pharmacological effects such as jingyeong, sedation, blood pressure lowering, vasodilation, antibacterial action, and antifungal action (Korean Society Tabacco Sci., 1994, 16, 20-25). It is used for diseases such as menstrual irregularity, tonic, coldness, and anemia.

Corydalis Tuber is a perennial herb of the Papaveraceae, which uses tubers of Corydalis ternate Nakai or other homologous root plants. Alkaloids such as Tetrahydropalmatine, protopine, corydaline, dehydrocorydaline, and hydrastine have been reported separately (Qicheng, F., Hao, H., Planata med. , 1986, 32, 193-198). Inhibitory activity, platelet aggregation inhibitory activity, anti-inflammatory and aldose reductase activity, GABA receptor inhibitory activity (Sheng Li Hsuch Pae 1957, 21, 150-157; Sheng Li Hsuch Pae 1964, 27, 47-58) Planta Med., 1988, 54, 498-501; Biol. Pharm. Bull., 1994, 17, 458-459; Br. J. Pharmacol., 1990, 99, 727-730). In ancient medicine, it has been used for blood clots, analgesic, jingyeong, peptic ulcer, headache, abdominal pain, dysmenorrhea, etc.

In addition, the mixed extracts of the uterus and cortex of the present invention can prevent or treat respiratory diseases due to the activity of inhibiting the activity of 5-lipoxygenase (5-lipoxygenase, 5-LO). 5-lipoxygenase is known to be the major action enzyme required to produce leukotrienes (LTs) from arachidonic acid (Science, 1983, 220, 568-75). The leukotriene thus produced is known to be a major cause of airway contraction and inflammation, which is a serious symptom in respiratory diseases including asthma, bronchitis, and the like. The production of these leukotrienes by inhibiting 5-lipoxygenase It is thought to be able to cure respiratory diseases mainly by blocking airway contraction and relieving inflammation.

The production of leukotrienes by 5-lipoxygenase is as follows. First, IgE-mediated activation of mast cells (immune cells that are the main causes of allergy, surface factors to which IgE antibodies can attach to the surface of mast cells) is derived from IgE-mediated activation. By phospholipase A2 is activated by the phospholipidase A2, the phospholipidase generates arachidonic acid (arachidonic acid) from the phospholipids (phospholipids) in the cell membrane. In addition, as a signal for stimulation of mast cells, 5-lipoxygenase is transferred from the cytoplasm to the nuclear membrane, and 5-lipoxygenase activating protein in the cytoplasmic nuclear membrane is used to inhibit 5-lipoxygenase. Activated (Science, 1983, 220, 568-75). The activated 5-lipoxygenase oxidizes arachidonic acid, thereby converting arachidonic acid to hydroperoxyeicosatetraenoic acid (HPETE), which is produced by LTA synthase (LTA synthase, Rukotriene A synthase). To LTA4 (Lucotriene A4) and then to LTB4 (Lucotriene B4) or LTC4 (Lucotriene C4) (Science, 1983, 220, 568-75).

LTA4 (Lucotriene A4) is converted to LTB4 by LTA4 hydroxylase (LTA4 hydroxylase). Alternatively, LTA4 (Lucotrienne A4) is converted to LTC4 (Lucotrienne C4). ) Is converted to LTC4 (rucotriene C4) by synthetase. The LTC4 (rucotriene C4) thus produced is transported out of cells and metabolized to LTD4 (rucotriene D4) and LTE4 (rucotriene E4) (Science, 1983, 220, 568-75).

LTB4 (Luctorien B4) is a powerful chemoattractant such as neutrophils, eosinophils, and monocytes, attaching phagocytes to the vessel wall and degranulating neutrophils. It is known as a major factor that causes airway inflammation by producing superoxide anions. LTC4 (Lucotriene C4) and its metabolite LTD4 (Lucotriene D4) are potent bronchoconstrictors known to increase vascular permeability and increase mucous secretion of the airways (Science, 1983, 220). , 568-75).

LTC4 (rucotriene C4), LTD4 (rucotriene D4) and LTE4 (rucotriene E4) all have cysteine residues, collectively called cysLTs, most of which are mast cells Produced in neutrophils, eosinophils, and alveolar macrophage, acts on cysLT1 (cysLT receptor type 1) to stimulate airway smooth muscle, causing airway contraction, and inflammatory reactions in respiratory diseases such as mucus hypersecretion and asthma Are known to be the major contributing factors (Science, 1983, 220, 568-75).

Inhibition of 5-lipoxygenase effectively blocks the production of these leukotrienes and can be used to treat respiratory diseases mainly by suppressing airway contraction, suppressing mucous secretion and reducing inflammation (Curr Med Chem). ., 2007, 14, 1966-77; Prostaglandins & Lipid Mediators, 2007, 83, 188-97; Pediatrics, 2008, 122, e1249-55). Confirmed that it is markedly elevated, 5-lipoxygenase inhibitory activity, airway contraction inhibitory activity, airway inflammation inhibitory effect and ear edema anti-inflammatory effect, the highest efficiency synergistic effect of the mixed extracts of cheongung and sageum produced Thus, the present invention has been completed.

Korean Patent Laid-Open Publication No. 2006-128153, which discloses ethanol extract of cheongungung in the prior art, has an anti-inflammatory effect by inhibiting 5-lipoxygenase activity, but it is an invention related to a composition containing cheongung extract excellent in treating acne, The use of the composition is limited to cosmetics, and furthermore, it is not disclosed in the detailed description of the invention until the extract has a therapeutic effect against inflammation of respiratory diseases by inhibiting 5-lipoxygenase activity.

It has also been disclosed that water extracts of medicinal herbs containing the uterus inhibit bronchospasm induced by histamine and acetylcholine in the guinea pig model and are also effective in allergic infections (Zhongguo Zhong Xi Yi Jie He). Za Zhi, 1994, 14 [8], 465-8), the extract is a water extract, the literature does not disclose alcohol extracts.

For the Corydalis extract, Korea Patent No. 2010-11449 disclose a number extract the organic solvent, including water or alcohol containing a geumryeongja Corydalis and the induced by LPS (lipopolysaccharide) from mouse macrophages for NO (nitric oxide), PGE ₂ (prostaglandin E ₂ ), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) expression, and anti-inflammatory effects, including respiratory inflammation of asthma or rhinitis, have been shown to inhibit the production of inflammatory cytokines. It differs from the present invention containing a mixed extract of and corydalis.

In addition, Korean Journal of Oriental Physiology No. 19, No. 3, page 785-791 discloses that the water extract of Hyunho color has an anti-inflammatory effect. Although disclosed as useful for the treatment of asthma, it is also different from the present invention, which contains a mixed extract of the uterus and corydalis.

In addition, herbal extracts containing Hyunho color and Cheongung were inhibited in the production of NO in mouse macrophages in Korean Journal of Oriental Physiology and Pathology No. 20, No. 4, pages 957-965 and Korean Journal of Oriental Medical Gynecology, Vol. 21, No. 4, pages 49-68. It is disclosed that the production of IL-1β (interleukin-1β), IL-6 (interleukin 6), and TNF-α (tumor necrosis factor-α) is inhibited in red and mice, but the herbal extract is water extract. As the extraction conditions are different from the present invention, and the therapeutic effect on the inflammatory diseases of the respiratory diseases through the inhibitory activity of 5-lipoxygenase is not disclosed and is different from the present invention.

An object of the present invention is to provide a composition for the prevention or treatment of respiratory diseases containing a mixed herbal extract of cheongung and Hyunho colors as an active ingredient.

It is still another object of the present invention that the 5-lipoxygenase inhibitory activity, airway contraction inhibitory activity, airway inflammation inhibitory effect and anti-edema anti-inflammatory effect in mixed herbal extracts of celestial and endosperm are remarkably superior to that of single medicinal herb extract of celestial or corydalis. To check.

The present invention relates to a mixed extract having a 5-lipoxygenase inhibitory activity, an airway contraction inhibitory activity, an airway inflammation inhibitory effect, an ear edema anti-inflammatory effect, and a method for preparing the same, containing the mixed herbal extracts of the horoscope and sinusoida.

In the mixed herbal extracts of the cheonggung and Hyunho color according to the present invention, the extract refers to a crude extract or a fraction that is a specific solvent soluble extract of the crude extract, which may be in solution, concentrate or dry powder.

The present invention has a significant effect on 5-lipoxygenase inhibitory activity, airway contraction inhibitory activity, airway inflammation inhibitory activity and ear edema inflammation compared to the case of using a single herbal extract of cheon-ung or Hyun-ho color by using a mixed herbal extract of cheon-ung and Hyun-ho color. In particular, in vivo animal experiments showed significant respiratory disease treatment effects.

In the mixed extracts of the arch and chorus of the present invention, the mixing ratio of the arch and the chorus is 0.1: 1 to 10: 1 based on the weight of the herb. More preferably, it is 0.3: 1-3: 1.

The mixed herbal extract according to the present invention may be a crude extract (primary extract) or concentrate thereof obtained by extraction with a lower alcohol having 1 to 4 carbon atoms or an aqueous solution thereof. The lower alcohol having 1 to 4 carbon atoms may be preferably selected from ethanol, methanol, propanol, isopropanol and butanol. The mixing ratio of the alcohol in the aqueous alcohol solution of 1 to 4 carbon atoms may be mixed in 10 to 95% (v / v), preferably 30 to 95% (v / v). When using butanol as the extraction solvent, it is preferable to use saturated butanol (75-85% v / v butanol aqueous solution). At this time, the extraction temperature is preferably 40 to 120 ℃, preferably 60 to 90 ℃, extraction time is 2 to 24 hours, preferably 4 to 12 hours.

In addition, the crude herbal extracts (primary extracts) of the cheon-ung and Hyun-ho colors are concentrated, and these are further added to the lower alcohols having 1 to 4 carbon atoms, their aqueous solutions or non-polar solvents individually (or in combination), and further divided into fractions (2). Tea extract). The lower alcohol having 1 to 4 carbon atoms may be preferably selected from ethanol, methanol, propanol, isopropanol and butanol. The nonpolar solvent may be selected from the group consisting of ethyl acetate, dichloromethane, chloroform and butanol. At this time, the extraction temperature is preferably 40 to 120 ℃, preferably 60 to 90 ℃, extraction time is 2 to 24 hours, preferably 4 to 12 hours.

Furthermore, 5-20 times (v / w) purified water was added to the concentrates of the crude herbal extracts (primary extracts) of the cheon-ung and Hyun-ho color, followed by suspension, followed by ethyl acetate, dichloromethane, chloroform and butanol (saturated). Butanol) in the organic solvent group consisting of (or sequentially) can be added separately to extract it to obtain a fraction (secondary extract). At this time, the extraction temperature is preferably 40 to 120 ℃, preferably 60 to 90 ℃, extraction time is 2 to 24 hours, preferably 4 to 12 hours.

Extract of the present invention is not limited to the number of extraction depending on the extraction efficiency.

When the amount of the solvent used in the preparation of the mixed herbal medicine extract of cheonggung and Hyunho color is too low, the solubility of the extract is low, the extraction efficiency is reduced, and the filter is clogged during filtration, and when too much, the amount of lower alcohol is used. The amount of solvent to be used is preferably within the above range because it is not economical and may cause problems in handling.

In the present invention, a method of re-fractionation after the first extraction was selected. This is because when the extract of the herbal medicine is extracted in a large amount, even though the extract is filtered after the first extraction, the extraction efficiency is increased because the content of the extraction solvent is high in the herbal medicine itself. This is to prevent falling. In addition, as a result of verifying the extraction efficiency of each step, it was confirmed that about 90% of the total extraction amount was extracted by the first and second extraction, and the third or more extraction method was inefficient due to economic efficiency compared to the yield. Judging.

The crude extracts or fractions thus obtained are 2 to 10 times (v / w), preferably 4 to 6 times (v / w) relative to the weight of the concentrate in order to remove residual lower alcohols suitable for use as pharmaceutical raw materials. Azeotropically concentrated 2 to 8 times with water and suspended again homogeneously by addition of water, and then mixed extracts of powdery celestial and calendula colors can be prepared using conventional drying methods such as reduced pressure drying, spray drying, or freeze drying. .

As the extraction method used in the present invention, all conventionally used methods may be used, and for example, immersion (cold and warm), hot water extraction, ultrasonic extraction, or reflux cooling extraction may be used, but is not limited thereto.

According to another aspect of the present invention, the mixed herbal extracts of the hormonal and sinusoidal colors exhibit significantly elevated 5-lipoxygenase inhibitory activity, airway contraction inhibitory activity, airway inflammation inhibitory activity, and edema anti-inflammatory effect than each single herbal extract. Because of the bet, it can be usefully used for preventing or treating respiratory diseases or symptom relief.

Accordingly, the present invention provides a composition for the prevention or treatment of respiratory diseases comprising a mixed herbal extract of cheonggung and Hyunho colors as an active ingredient.

The respiratory disease may be any disease causing inflammation and airway contraction, generally acute bronchitis, catarrhal bronchitis, obstructive bronchitis, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE mediated asthma, It may be a disease selected from the group consisting of allergic asthma, non-allergic asthma, chronic bronchial contraction, acute bronchial contraction, chronic obstructive pulmonary disease, antitussive expectoration, bronchial adenoma, pulmonary tuberculosis, emphysema and lung abscess.

The content of the mixed extract as an active ingredient in the composition according to the present invention may be appropriately adjusted according to the use form and purpose, the severity of the patient, etc., and may be 0.01 to 99.9% by weight, preferably 0.1 to 50% by weight, based on the weight of the solids. However, the present invention is not limited thereto.

In addition, the composition may be administered in various oral and parenteral dosage forms during actual clinical administration, and when formulated, diluents or excipients such as fillers, weights, binders, wetting agents, disintegrating agents, and surfactants that are commonly used may be used. Can be used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which solid preparations comprise at least one of a specific solvent soluble extract of crude and corydale crude extracts and crude extracts, or compounds isolated therefrom. The above excipients such as starch, cellulose, calcium carbonate, crospovidone, light silicic anhydride, lactose, magnesium stearate, talc, enzymatically treated stevia, microcrystalline cellulose, magnesium stearate, gelatin and the like can be used in combination. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations. Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.

The dosage of the mixed extract-containing composition of the present invention may vary depending on the patient's worm, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of the disease, and according to the judgment of the doctor or pharmacist It may be administered once or several times a day at intervals of time. For example, the daily dose may be 0.001 to 500 mg / kg, preferably 0.1 to 200 mg / kg, based on the active ingredient content.

In another aspect, the present invention provides a health functional food for the prevention or improvement of respiratory diseases, such as asthma, acute bronchitis, chronic obstructive pulmonary disease containing a mixed extract of cheongung and Hyunho colors. The health functional food may be various foods, beverages, food additives and the like.

The content of the mixed extract as an active ingredient contained in the health functional food may be appropriately contained according to the form of the food, the intended use, for example, may be added to 0.01 to 50% by weight of the total food weight, preferably Can be added at a ratio of 0.1 to 10% by weight. In addition, the health beverage composition may be added in a ratio of 0.02 to 10g, preferably 0.1 to 5g based on 100ml.

In addition to containing the extract as an essential ingredient in the indicated ratio, the health beverage composition of the present invention is not particularly limited in the liquid component and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0.001 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

In particular, the cheongung and Hyunho colors of the present invention are considered to have no side effects compared to other synthetic medicines when administered to humans as herbal medicines that have been used in oriental medicine since ancient times. The results were found to have no effect in vivo.

It was confirmed that the mixed extracts of cheonggung and Hyunho colors according to the present invention have superior 5-lipoxygenase inhibitory activity, airway contraction inhibitory activity, airway inflammation inhibitory effect and ear edema anti-inflammatory effect. It was confirmed that the extracts or fractions were mixed at the optimum ratio. In addition, the present invention shows a good effect in animal models of various anti-asthmatic diseases, unlike the conventionally used therapeutics, asthma (bronchial asthma, atopic asthma, atopic bronchial IgE mediated asthma, non-atopic asthma, allergic asthma) And non-allergic asthma, etc.), acute bronchitis, as well as chronic obstructive pulmonary adenoma, pulmonary tuberculosis, empyema, lung abscess, cough expectoration, allergic rhinitis, acute respiratory tract infection (bronchitis and bronchiolitis), catarrhal bronchitis and obstructive or inflammatory It is thought to be very useful for respiratory diseases such as bronchial disease, sore throat, tonsillitis and laryngitis.

Fig. 1 shows bronchial contraction inhibitory activity after treatment of the extract bronchus of guinea pigs with 0.3 mg / ml of the extracts of Examples 1 to 33 and Comparative Examples 1 to 5;

Hereinafter, a preferred embodiment of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the concept of the invention to those skilled in the art.

Example 1 Preparation of 50% Ethanol Extract of Cheongung + Hyunho Color (1: 1)

50 g of Cheongung and 50 g of Hyunho red color were mixed and extracted with 1000 ml of 50% ethanol aqueous solution at reflux for 2 hours at 88 ° C., followed by filtration and concentration under reduced pressure. Distilled water 5 times more than the weight of the concentrate was added to the obtained concentrate, suspended, and lyophilized to obtain 15.1 g of a mixed crude extract of the powder form of cheon-ung and chalcedony.

Example 2 Preparation of Butanol Fraction of 50% Ethanol Solution in Cheonung + Hyunho Color (1: 1)

Suspended by adding 10 times (v / w) of purified water to the crude extract prepared according to the preparation method of Example 1 and added the same amount butanol (80% butanol aqueous solution) two times separated and separated butanol Bay was collected, filtered and concentrated under reduced pressure. About 100 ml of purified water was added while the butanol and purified water were evaporated, and then azeotropically concentrated, and then repeated twice to completely remove butanol. The concentrate thus obtained was further suspended by adding distilled water five times the weight of the concentrate, and then lyophilized to obtain 2.0 g of a powdery fraction.

The following Examples 3 to 33 and Comparative Examples 1 to 5 were carried out under the conditions of Table 1, but other conditions were performed in the same manner as in Examples 1 and 2. However, in the case of water extract, the mixture was cooled by reflux extraction for 8 hours with water, filtered, and immediately lyophilized.

Experimental Example 1: 5-lipoxygenase inhibitory effect

The following method was performed by using the cells to evaluate the activity inhibitory ability of the mixed extracts prepared by Examples 1 to 33 and the extracts prepared by Comparative Examples 1 to 5, which are the primary pathogenesis of asthma, the rucotriene producing enzyme. The results were as shown in Table 2.

To this end, rat basophilic leukemia cells (Rat basophilic leukemia cells, RBL-1) were stabilized at 37 ° C. using RPMI medium without serum, and then extracts were added and arachidonic acid (arachidonic acid) was added as a substrate. Lucotriene was produced for a minute. The amount of produced rucotrienes was measured using a cysteinyl leukotriene EIA kit. Positive controls were zileuton and montelukast, inhibitors of 5-lipoxygenase.

As shown in Table 2, the mixed extracts of Examples 1 to 33 of the present invention was found to have an excellent effect of inhibiting 5-lipoxygenase, and the mixed herbal extracts or fractions of cheonggung and Corydalis compared to the activity of a single herbal extract. It was confirmed that there was a remarkable 5-lipoxygenase inhibitory effect by the synergistic effect of the use of these crossbows and sinusoids in combination.

Experimental Example 2 Bronchial Contraction Inhibition Test in vitro )>

In order to evaluate the bronchial contraction inhibitory activity of the mixed extracts prepared in Examples 1 to 33 and the extracts of Comparative Examples 1 to 5, the following method was used to extract bronchial bronchus (Nature, 1977, 270, 256-257; Jpn). J. Pharmacol., 1996, 72, 1-8; Kor. J. Pharmacogn. 1999, 30 [4], 377-383), and the results are shown in FIG. In Figure 1 positive control rolipram (rolipram) was 20μM, each extract was treated with 0.3mg / ㎖, the inhibition rate of bronchial contraction (%) for each concentration is shown in Table 3.

To this end, Hartley male guinea pigs (400-500 g, BGI, Korea) were sensitized by intravenous injection of anti-ovalbumin anti-serum at a volume of 2 ml / kg. 48 hours after sensitization, guinea pigs were bled and the bronchus was removed. Thereafter, the other tissues attached to the bronchus were removed from the thyroid liquid, and the cartilage was cut in a ring shape so that two to three cartilages were included. After the incision, the cartilage of the ring was cut while preserving the bronchial muscles, the threads were connected to both sides, and then suspended in an organ bath. After stabilization of a certain time, 10 μg / ml of carbachol was added. Maximum contraction was induced, and the bronchus was washed and stabilized with tyrode fluid. After this, 5 μM of indomethacin (indomethacin) was added and the extract was added after 1 minute, and after 5 minutes, 20 μg / ml of ovalbumin was added to cause contraction. Shrinkage (%) was calculated by comparing the contraction by carbacol and egg albumin. Bronchoconstriction was measured using a physiological activity meter (powerlab 8/30, ADInstument) connected to a force transducer (WPI).

As shown in Figure 1, the mixed extract of the arch and chorus of the embodiment has a bronchial contraction inhibitory activity, it can be seen that the dose-dependent excellent activity. In addition, compared to the inhibitory activity of bronchial contraction of a single herbal extract, it was confirmed that the mixed extract or fraction of the arch and chorus color have a significant inhibitory effect.

Experimental Example 3 Airway Shrinkage Inhibition Test in vivo )>

Respiratory volume measurement in guinea pigs to evaluate the airway contraction inhibitory activity of the extract of Example 9 and the extract of Comparative Examples 1 to 5 excellent in bronchial contraction inhibitory activity in Experimental Example 2 (European Journal of Pharmacology, 2000, 403, 169- 179; Br. J. Pharmac., 1983, 78, 67-74) was carried out by the following method, the results are shown in Table 4 below.

Hartley male guinea pigs (400-450 g, SLC, Japan) were sensitized by intravenous injection of anti-albumin antiserum at a volume of 1.5 ml / kg. 48 hours after sensitization, the preparation to be tested for guinea pigs was administered orally. Thirty minutes after oral administration, pyrilamine maleate (0.5 mg / kg) and proranolol (propranolol (0.05 mg / kg) were injected subcutaneously and pretreated. The standard airway resistance (RxV) was measured in a double chamber plethysmograph box type 855 (HSE, German) equipped with a plethysmometer. After 30 minutes of pretreatment, 1% egg albumin was aerosolized using high pressure compressed air, sprayed for 2 minutes, and air containing albumin was flowed out for 30 seconds. Airway resistance was then measured in a pletismometer box for 15 minutes and airway resistance was calculated by AUC (area under the curve), and is shown as percent inhibition in Table 4 compared to solvent control. Montelukast was used as a positive control in this experiment.

As shown in Table 4, it can be seen that the mixed extracts of the uterus and corolla of the embodiment of the present invention exhibited a dose-dependent superior activity in the airway contraction inhibitory effect of sensitized guinea pigs. It was confirmed that the mixed extract or fraction of cheongung and Hyunho color have a significant inhibitory effect.

Experimental Example 4: Bronchial Inflammation Inhibition Test

In order to determine whether the extracts of Example 9 and the extracts of Comparative Examples 1 to 5 excellent in bronchial contraction inhibitory activity in Experimental Example 2 have an inhibitory effect on the bronchial inflammation in the mouse asthma model, antigens were exposed to sensitized mice. Leukocyte increase response of the induced bronchiole was confirmed (Pharmacological Research, 2010, 61, 288-297; Biochemical Pharmacology, 2010, 79, 888-896), and the results are shown in Table 5.

To this end, BALB / c female mice (6.5 weeks old, SLC, Japan) were mixed with 0.2 ml of 10 μl of egg albumin (Ovalbumin, OVA, sigma) and Alum (Pierce) 1: 1 mixture for 0, 7 and 14 days. Intraperitoneal administration to sensitization. After 8 and 10 days of final sensitization, 1.0% egg albumin was aerosolized using high-pressure compressed air and sprayed for 50 minutes to induce airway inflammation. 10 mg / kg of rolipram (sigma) was used as a positive control drug, and the administration of the positive control drug and the test substance was administered orally twice a day from 21 to 23 days after sensitization. Morning administration on the day of challenge was performed 1 hour before challenge. 24 hours after the last inflammation, the waste broth was washed with 1.5 ml of phosphate buffer (pH 7.2) to collect the washing solution. White blood cell count in the cleaning solution was counted using a fractional matol H. Lodge analyzer ^{(? Hematology analyzer, Drew Scientific Inc.} , HEMAVET HV950FS, M-950HV). The results are shown in Table 5 below to calculate the inhibition rate (%) based on the leukocyte cell count of the negative control group (1% CMC [carboxymethyl cellulose] administration group).

As shown in Table 5, it was confirmed that the leukocyte increase in bronchial bronchus induced when exposing the antigen to the sensitized mouse of the extract of the present invention is dose-dependently inhibited. In addition, it was confirmed that the mixed extracts or fractions of the arches and corydalis had a significant inhibitory effect as compared to the anti-bronchial inflammation inhibitory activity of the single herbal extract.

Experimental Example 5: Anti-inflammatory inhibitory effect test against ear edema

To evaluate the anti-inflammatory activity of the extracts of Example 9 and the extracts of Comparative Examples 1 to 5 excellent in bronchial contraction inhibitory activity in Experimental Example 2, a mouse inducing edema with croton oil was used. The results are shown in Table 6. Croton oil, when applied to the skin, causes inflammatory effects of redness, swelling and blisters on the surface of application (Archives of Pharmacal Research, 1993, 16 [1], 18-24).

As the experimental animals, 10 male ICR mice (Oriental Bio, Korea) weighing 20-23 g were used in each group. The mice fasted the previous day were orally administered with a sample and a positive control group COX-2 inhibitor celecoxib (100 mg / kg, Celecoxib, Pfizer), and 3% croton oil dissolved in acetone after 1 hour in the right ear of the mouse. It was applied evenly on the inside and outside to cause edema of the ear. Four hours after the induction of edema, the mouse was anesthetized with ether, and both ears were measured for the degree of edema of the mouse by a speed change method using a thickness gauge, and edema of the negative control group (1% CMC-administered group). Based on the degree of inhibition (%) was calculated in Table 6 below.

As shown in Table 6, the extract prepared as an embodiment of the present invention shows a dose-dependent excellent activity in the inhibitory effect in the edema inflammatory animal model of mice induced with croton oil, the activity of a single herbal extract It was confirmed that the mixed extract or fraction of cheongung and Hyunho color have a significant inhibitory effect.

Experimental Example 6. Toxicity Test

6-1. Acute Toxicity

The extract of Example 2 of the present invention was carried out to determine the toxicity of a single oral administration to rats of Sprague-Dawley (SD) strain. The extracts were administered at doses of 1,000, 2,000 and 4,000 mg / kg in a single dose (10 males and 5 males) per group, followed by mortality, general symptoms, body weight and necropsy findings compared to the excipient controls.

the results are as follow. No dead animals were observed during the test period, and weight change observations showed no changes in body weight associated with the administration of the test substance. Abnormal findings were not observed in the autopsy findings.

In view of the above results, the extract of Example 2 of the present invention, when administered orally to Sprague-Dawley male and female rats, the minimum lethal dose (MLD: Minimum Lethal Dose) was judged to exceed 4,000 mg / kg in both sexes It was found to be a safe substance.

6-2. Repeated dose toxicity test

The extract of Example 2 of the present invention was carried out to determine the schematic toxicity by repeated oral administration for 2 weeks. A test group in which doses of 1,000 and 2,000 mg / kg / day of test substance were administered to Sprague-Dawley male and female rats was set, and an excipient control group in which only an excipient was administered was set. The number of animals was 5 male and female in each group. Test items were mortality, general symptoms, weight change, feed and water intake, urinalysis, hematology and blood biochemistry, autopsy findings, organ weight and histopathological findings.

The test results are as follows. No dead animals related to the toxicity of the test substance were observed during the study period, and no change in general symptoms related to the administration of the test substance was observed. As a result of weight change, no significant change was observed by the administration of test substance, and no significant change by the administration of test substance was observed. Urinary tests and hematology and blood biochemical tests showed no toxicological abnormalities associated with the administration of this test substance. Long-term weight and gross necropsy findings showed no gross abnormalities associated with the administration of the test substance, and histopathological findings showed no toxicological abnormalities associated with the administration of the test substance.

In view of the above results, the extract of Example 2 of the present invention was confirmed to be a safe substance as a non-toxic amount (NOAEL) was determined to be 2,000 mg / kg / day in both male and female as a result of repeated oral administration test for SD rats for 2 weeks.

Preparation Example 1 Preparation of Tablet

Mixed extract of Example 2 ... 200 mg

Corn starch ............... 50 mg

CELLACTOOSE ......................................... 100 mg

Crospovidone ......................................... 20 mg

Hard silicic anhydride ........................... 5 mg

Lactose ... .. 70 mg

Magnesium Stearate ......................................... 5 mg

After mixing the above components, tablets were prepared by tableting according to the usual preparation method of tablets.

Preparation Example 2 Preparation of Powder

Mixed extract of Example 2 ... 200 mg

Corn starch ............... 50 mg

Lactose ... 100 mg

Talc ........................ 10 mg

The powders were prepared by mixing the above components and filling the airtight cloth according to a conventional powder preparation method.

Preparation Example 3 Preparation of Granules

Mixed extract of Example 2 ... 300 mg

Corn starch ..................... 1000 mg

Lactose ......................................... 1000 Mg

Enzyme Treatment Stevia ... 50 mg

Talc ........................ 10 mg

The powders were prepared by mixing the above components and filling them in airtight cloths according to a conventional granulation method.

Preparation Example 4 Preparation of Capsule

Mixed extract of Example 2 ... 300 mg

Microcrystalline cellulose ......................................... 150 mg

Lactose ......................................... 30 mg

Magnesium Stearate ......................................... 0.5 mg

Capsules were prepared by mixing the above ingredients and filling the gelatin capsules according to a conventional capsule preparation method.

Preparation Example 5 Preparation of Injection

Mixed extract of example 2 ... 50 mg

Mannitol ... Mg

Sterile Distilled Water for Injection ............... 3500 ml

Na ₂ HPO _{4 ,} 12H ₂ O ......................................... .. 20 mg

pH adjuster .....................

Injectables were prepared by dissolving the active substance and the rest of the ingredients in sterile distilled water for injection, adjusting the pH to about 7.5 according to a conventional injection method, and filling a 2 ml ampoule with sterilized distilled water for injection.

Preparation Example 6 Preparation of Liquid

Mixed extract of Example 2 ............... 500 mg

Isomerized sugar ......................................... 10 g

Mannitol ... 5 g

Purified water ................................................. Appropriate amount

According to the conventional method of preparing a liquid solution, each component is added and dissolved in purified water, orange micron is added to the appropriate amount, the above components are mixed, purified water is added to adjust the total amount to 100 ml, and the container is filled and sterilized to prepare a liquid solution. do.

Preparation Example 7 Preparation of Health Foods

Mixed extract of Example 2 ... 500 mg

Vitamin Blend ...............

Vitamin A Acetate ......................... 70 μg

Vitamin E ........................................ 1.0 mg

Vitamin B1 ............................................... 0.13 mg

Vitamin B2 ......................................... 0.15 mg

Vitamin B6 ......................................... 0.5 mg

Vitamin B12 ......................... 0.2 μg

Vitamin C ............................................... 10 Mg

Biotin ... 10 μg

Nicotinic Acid Amide ......................................... 1.7 mg

Folic Acid ... 50 μg

Calcium Pantothenate ......................................... 0.5 mg

Mineral mixture ...............

Ferrous Sulfate ....................................................... 1.75 Mg

Zinc Oxide ......................................... 0.82 mg

Magnesium Carbonate ......................................... 25.3 mg

Potassium monophosphate ......................................... 15 mg

Dicalcium Phosphate Dioxide ......................................... 55 mg

Potassium Citrate ......................................... 90 mg

Calcium Carbonate ......................................... 100 mg

Magnesium Chloride ......................................... 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Preparation Example 8 Preparation of Healthy Drinks

Mixed extract of Example 2 ... 200 mg

Citric Acid ... Mg

Oligosaccharide ....................................................... 100 g

Plum concentrate ........................................ 2 g

Taurine ... 1 g

Purified water is added ..................... 900 ml total

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (9)

A composition for the prophylaxis or treatment of respiratory diseases, characterized in that it contains an extract of the mixture of cheongung and Hyunho color as a lower alcohol having 1 to 4 carbon atoms or an aqueous solution of 10-95% alcohol thereof as an active ingredient. The method of claim 1,
The extract is a composition for the prevention or treatment of respiratory diseases, characterized in that the extract is soluble purified by a solvent selected from the group consisting of ethyl acetate, dichloromethane and butanol. The method according to claim 1 or 2,
The herbal mixture weight ratio of the mixture of the cheongung and Hyunho color is a composition for the prevention or treatment of respiratory diseases, characterized in that the cheongung: Hyunho color is 0.1: 1 to 10: 1. The method of claim 3, wherein
Said herbal mixture weight ratio is a composition for the prevention or treatment of respiratory diseases, characterized in that the crossbow: Hyunho color 0.5: 1 ~ 5: 1. The method according to claim 1 or 2,
The respiratory disease is prevented or treated for asthma, chronic obstructive pulmonary disease, allergic rhinitis, bronchial adenoma, pulmonary tuberculosis, empyema, lung abscess, cough fungus, bronchitis, sore throat, tonsillitis and laryngitis Composition. The method of claim 5, wherein
The asthma is selected from the group consisting of bronchial asthma, atopic asthma, atopic bronchial IgE-mediated asthma, non-atopic asthma, allergic asthma and non-allergic asthma, composition for the prevention or treatment of respiratory diseases. The method of claim 5, wherein
The bronchitis is acute bronchitis, chronic bronchitis, bronchiolitis, catarrhal bronchitis and obstructive and inflammatory bronchial disease, characterized in that the composition for the prevention or treatment of diseases of the respiratory organs. Health functional food for the prevention or improvement of respiratory diseases, characterized in that the mixture containing the extract of cheongung and Hyunho color as a lower alcohol having 1 to 4 carbon atoms or an aqueous solution of 10-95% alcohol thereof as an active ingredient. The method of claim 8,
The extract is a dietary supplement for the prevention or improvement of respiratory diseases, characterized in that the extract is soluble purified with a solvent selected from the group consisting of ethyl acetate, dichloromethane and butanol.

Images